Human papilloma virus immunoreactive peptides

Details Human papilloma virus immunoreactive peptides Human papilloma virus immunoreactive peptides

2007-03-13

2007-03-13

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S069100, C435S325000

Reexamination Certificate

active

10472661

ABSTRACT:
This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.

REFERENCES:
patent: 4551270 (1985-11-01), Danos et al.
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 5279833 (1994-01-01), Rose
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5719054 (1998-02-01), Boursnell et al.
patent: 5985270 (1999-11-01), Srivastava
patent: 6004557 (1999-12-01), Edwards et al.
patent: 6183746 (2001-02-01), Urban et al.
patent: 75535/87 (1988-01-01), None
patent: 256321 (1988-01-01), None
patent: 386734 (1990-09-01), None
patent: 412762 (1991-02-01), None
patent: 2643817 (1990-09-01), None
patent: 01061665 (1989-03-01), None
patent: WO 86/05816 (1986-10-01), None
patent: WO 87/01375 (1987-03-01), None
patent: WO 90/10867 (1990-10-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 93/22338 (1993-11-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 96/40095 (1996-12-01), None
patent: WO 97/41440 (1997-11-01), None
Abcarian et al., “The Immunotherapy of Anal Condyloma Acuminatum.”Dis. Colon Rectum. 19(3):237-244 (Apr. 1976).
Abcarian et al., “Long-term Effectiveness of the Immunotherapy of Anal Condyloma Acuminatum.”Dis. Colon Rectum. 25(7):648-651 (Oct. 1982).
Abcarian et al., “The Effectiveness of Immnotherapy in the Treatment of Anal Condyloma Acuminatum. ”J. Surg. Res.22:321-236 (1977).
Babbitt et al., “Binding of immunogenic peptides to la histocompatibility molecules.”Nature317:359-361 (Sep. 1985).
Brown et al., “Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.”Nature364:33-39 (Jul. 1, 1993).
Bunney, “Viral warts: a new look at an old problem.”Br. Med. J. 293:1045-1047 (Oct. 25, 1986).
Buus et al., “Isolation and Characterization of Antigen-la Complexes Involved in T Cell Recognition.”Cell47:1071 (1986).
Engelhard, “Structure of peptides associated with MHC class I molecules.”Curr. Opin. Immunol. 6:13-23 (1994).
Felgner et al., “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure.”Proc. Natl. Acad. Sci. USA84:7413-7417 (Nov. 1987).
Frazer et al., “Association between anorectal dysplasia, human papillomavirus, and human immunodeficiency virus infection in homosexual men.”Lancet657-660 (Sep. 20, 1986).
Fremont et al., “Crystal Structure of I-Akin Complex with a Dominant Epitope of Lysozyme.”Immunity8:305-317 (Mar. 1998).
Fremont et al., “Crystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2Kb,”Science257:919-927 (Aug. 14, 1992).
Germain and Margulies, “The biochemistry and cell biology of antigen processing and presentation.”Annu. Rev. Immunol. 11:403-450 (1993).
Guo et al., “Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle.”Nature360:364-366 (Nov. 26, 1992).
Guo et al., “Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A*0201, and HLA-B*2705.”Proc. Natl. Acad. Sci. USA90:8053-8057 (Sep. 1993).
Jamieson et al., “Effective Clearance of a Persistent Viral Infection Requires Cooperation between Virus-Specific Lyt2+T Cells and Nonspecific Bone Marrow-Derived Cells.”J. Virol. 61(12):3930-3937 (Dec. 1987).
Jones, “MHC class I and class II structures.”Curr. Opin. Immunol. 9:75-79 (1997).
Kast et al., “Role of HLA-A Motifs in Identification of Potential CTL Epitopes in Human Papillomavirus Type 16 E6 and E7 Proteins.”J. Immunol. 152:3904-3912 (1994).
Kirschner, “Immunobiology of Human Papillomarirus Infection.”Prog. Med. Virol. 33:1-41 (1986).
Kondo et al., “Prominent Roles of Secondary Anchor Residues in Peptide Binding to HLA-A24 Human Class I Molecules.”J. Immunol. 155:4307-4312 (1995).
Lukacher et al.J Exp Med. 160:814-826 (1994).
Madden et al., “The Three-Dimensional Structure of HLA-B27 at 2.1 Å Resolution Suggests a General Mechanism for Tight Peptide Binding to MHC.”Cell70:1035-1048 (Sep. 18, 1992).
Madden et al., “The Antigenic Identity of Peptide-MHC Complexes: A Comparison of the Conformations of Five Viral Peptides Presented by HLA-A2.”Cell75:693-708 (Nov. 19, 1993).
Madden. “The three-dimensional structure of peptide-MHC complexes.”Annu. Rev. Immunol. 13:587-622 (1995).
Mannino and Gould-Fogerite. “Liposome Mediated Gene Transfer.”Bio Techniques. 6(7):682-690 (1988).
Matsumura et al., “Emerging Principles for the Recognition of Peptide Antigens by MHC Class I Molecules.”Science257:927-934 (Aug. 14, 1992).
McMichael et al., “Cytotoxic T-cell immunity influenza.”N. Eng. J. Med. 309(1):13-17 (Jul. 7, 1983).
Meneguzzi et al., “Vaccinia recombinants expressing early bovine papilloma virus (BPV1) proteins: retardation of BPV1 tumour development.” Vaccine 8:199-204 (Jun. 1990).
Oldstone et al., “Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system.”Nature321:239-243 (May 15, 1989).
Olson et al., “Induced Immunity of Skin, Vagina, and Urinary Bladder to Bovine Papillomatosis.”Cancer Res. 22:463-469 (May 1962).
Olson et al., “Immuntiy to Bovine Cutaneous Papillomatosis Produced by Vaccine Homologous to the Challenge Agent.”J. Am. Vet. Med. Assoc. 135(10):499-502 (Nov. 15, 1959).
Parham et al., “The Origins of HLA-A,B,C Polymorphism.”Immunol. Rev. 143:141-180 (1995).
Pilacinski et al., “Development of a recombinant DNA vaccine against bovine papillomavirus infection in cattle.”UCLA Symp Molecular and Cellular Biology New Series. vol. 32.Papilloma Viruses Molecular and Clinical Aspects. Alan R. Liss, New York. p. 257-271 (1985).
Quinnan et al., “Cytotoxic T-cells in Cytomegalovirus Infection: HLA—Restricted T-Lymphocyte and Non-T-Lymphocyte Cytotoxic Responses Correlate with Recovery from Cytomegalovirus Infection in Bone-Marrow-Transplant Recipients.”N. Eng. J. Med. 307(1):7-13 (Jul. 1, 1982).
Rammensee et al., “MHC ligands and peptide motifs: first listing.”Immunogenetics41:178-228 (1995).
Reddenhase et al., “Intestitial Murine Cytomegalovirus Pneumonia After Irradiation: Characterization of Cells That limit Viral Replication During Established infection of the Lungs.”J. Virol. 55(2):263-273 (Aug. 1985).
Ruppert et al., “Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules.”Cell74:929-937 (Sep. 10, 1993).
Saper et al., “Refined Structure of the Human Histocompatibility Antigen HLA-A2 at 2-6 Å Resolution.”J. Mol. Biol. 219:277-319 (1991).
Sethi et al., “Protection of Mice from Fatal Herpes Simplex Virus Type 1 Infection by Adoptive Transfer iof Cloned Virus-specific and H-2-restricted Cytotoxic T Lymphocytes.”J. Gen. Virol. 64:443-447 (1983).
Sette and Grey. “Chemistry of peptide interactions with MHC proteins.”Curr. Opin. Immunol. 4:79-86 (1992).
Sette et al., “HLA supertypes and supermotifs: a fuctional perspective on HLA polymorphism.”J. Curr. Opin. Immunol. 10:478-482 (1998).
Sheil et al.Ninth Report of Australian and New Zealand Combined Dialysis and Transplant Registry. APS Disney, ed. 104-112 (1986).
Sidney et al., “Definition of an HLA-A3—Like Supermotif Demonstrates the Overlapping Peptide-Binding Repertiores of Common HLA Molecules.”Hum. Immunol. 45:79-93 (1996).
Sidney et al., “Specificity and Degeneracy in Peptide Binding to HLA-B7-Like Class I Molec

Affiliated with

Also associated with

Rating

Human papilloma virus immunoreactive peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human papilloma virus immunoreactive peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human papilloma virus immunoreactive peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3775808